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A combination of Adriamycin (a.k.a. Doxorubicin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) is the most commonly
used chemotherapy regime for Hodgkin lymphoma. This highly eﬀective treatment is associated with a signiﬁcant risk of
neutropenia. Various strategies are adopted to counter this commonly encountered problem, including dose modiﬁcation, use
of colony stimulating factors, and prophylactic or therapeutic use of antibiotics. Data to support these approaches is somewhat
controversial, and in keeping with the paucity of deﬁnitive evidence, there is a wide disparity in the management of neutropenia
in patients receiving ABVD chemotherapy. This paper summarizes the evidence for managing ABVD-related neutropenia during
the treatment of Hodgkin lymphoma.
1.Introduction
Hodgkin Lymphoma (HL) accounts for 10–15% of all
lymphomas in the western countries. It typically shows a
bimodal age distribution and accounts for 15% of all cancers
in the population aged 15–24 years [1]. The incidence of
HL, based on data from the United States and European
registries ranges from 2.3 to 3.2 per 100,000 men and 1.3 to
2.5 per 100,000 women. The estimated 5-year survival of all
HL patients is about 86%, but the survival drops to 53% in
patients older than 65 years of age (SEER database) [2].
HL is classiﬁed into classical HL and lymphocyte pre-
dominant type, based on diﬀerences in morphology, geno-
type, phenotype, and clinical behavior. Classical HL is again
subdivided into four distinct histological types: nodular
sclerosis, mixed cellularity, lymphocyte predominant and
lymphocyte depleted [3]. Patients present at various clinical
stages with or without B symptoms, as deﬁned by the
Cotswold staging system [4].
2. Advanced HodgkinTreatment Overview
Combined chemotherapy and radiation is the most eﬀective
treatment approach for early stage (I-II) HL. Chemotherapy
with involved ﬁeld radiation therapy (IFRT) is shown to
be superior to radiation therapy alone in a large EORTC
clinical trial [5]. A metaanalysis of twenty-three clinical trials
suggeststhatuseofthiscombinedmodalitytreatmentresults
in better tumor control and overall survival compared to
chemotherapy alone [6]. Most trials have shown that two to
fourcyclesofchemotherapywithIFRTisadequatetreatment
for early stage HL [5, 7, 8].
Advanced HL (deﬁned as presentation with tumor bulk
> 10cm, the presence of B symptoms, and/or stage III/IV
disease) is associated with a 30–40% failure rate following
anthracycline-based chemotherapy [9]. Six to eight cycles of
chemotherapyareconsideredoptimalintheinitialtreatment
of advanced HL, based on several clinical trials [10–14].
3. ABVD Chemotherapy
ABVD is the most commonly used treatment for both early
and advanced HL in the USA, and several other western
nations. Two hundred forty-six of 283 (87%) patients with
HLfromaUniversityofIowa/MayoClinicprospectiveobser-
vational database received ABVD as initial chemotherapy in
2003–present [15]. This regimen is also favored in densely
populated but less prosperous countries where the drugs2 Advances in Hematology
are available at costs fairly lower than those in the United
States. Several clinical trials have proven that ABVD is highly
eﬀective and has a favorable toxicity proﬁle in comparison
to other chemotherapy regimens used in advanced HL.
A CALGB randomized trial compared three regimens of
chemotherapy against each other in patients with advanced
HL:(1)MOPP(Mechlorethamine,vincristine,procarbazine,
and prednisone) alone—the then standard of treatment—,
given for 6 to 8 cycles (2) MOPP alternating with ABVD
for 12 cycles (3) ABVD alone for 6 to 8 cycles. ABVD was
shown to have a 5-year failure-free survival (FFS) of 61%
and an overall survival of 73%, and was as eﬀective as the
MOPP/ABVD alternating regimen and superior to MOPP
alone. It was also found to be less myelotoxic than either of
theMOPPcontainingregimensandhasbecomethestandard
oftreatmentforHLandthereferencearmfortrialsexploring
other novel chemotherapy combinations [10].
ABVD was also compared with two multidrug regimens
(MDRs) in the UK LY09 trial [16] which randomized pati-
ents to ABVD or two diﬀerent MDRs. At a median follow-
up of 52 months, no diﬀerences in event-free or overall
survival were noted between the treatment groups, but subs-
tantially more grade 3-4 adverse eﬀects were noted in the
patients receiving MDRs. The Italian GISL study [17]c o m -
pared ABVD, BEACOPP (bleomycin, etoposide, doxorubi-
cin, cyclophosphamide, vincristine, procarbazine, and pred-
nisone), and CEC (cyclophosphamide, lomustine, vindesine,
melphalan, prednisone, epidoxirubicin, vincristine, procar-
bazine, vinblastine, and bleomycin) with each other. There
was no diﬀerence in the overall survival between the arms,
but the BEACOPP regime showed a statistically signiﬁcant
improvementin5-yearPFS,comparedtoABVD(81%versus
65%, P = .038). However, BEACOPP was associated with
considerably higher rates of grade 3-4 anemia (16% versus
5%), neutropenia (54% versus 34%) and infections (14%
versus 2%).
ABVD was also compared against Stanford V, an abbre-
viated (12 week) polychemotherapy regimen developed to
minimize the late toxicity of chemotherapy for advanced HL.
A three arm Italian study evaluating ABVD, modiﬁed Stan-
ford V, and MOPPEBVCAD showed that OS was superior
in the ABVD group compared to the modiﬁed Stanford [14]
regime (90% versus 82% P = .04). However, the study was
criticized for the nonuniform and delayed use of radiation
therapy in the modiﬁed Stanford V arm. A UK NCRI
randomizedtrialof520patients,availableasanabstractonly,
also compared Stanford V to ABVD chemotherapy [18]. At
a median followup of 4 years, a preplanned interim analysis
shows no diﬀerence in PFS and OS between the two groups.
Pulmonary toxicity was higher in the ABVD group while
other toxicities were more common with Stanford V. Data




availableto treat HL,ABVD is still associated with signiﬁcant
adverse eﬀects. The typical duration of the treatment cycle is
28 days, and the standard doses of the drugs are provided in
Table 1.
Table 1: ABVD doses and schedule.
Drug Dosage and Route Days of Treatment
Doxorubicin 25mg/m2 I.V 1 and 15
Bleomycin 10mg/m2 I.V 1 and 15
Vinblastine 6mg/m2 I.V 1 and 15
Dacarbazine 375mg/m2 I.V 1 and 15
The commonest grade 3-4 acute adverse eﬀects of this
regime, based on the Italian GISL study, include neutropenia
(34%), alopecia (31%), nausea/vomiting (13%), anemia
(5%), thrombocytopenia (3%), infections (2%), constipa-
tion (2%), and mucositis (1%) [17]. Long-term toxicities
of ABVD chemotherapy include pulmonary toxicity (8%),
cardiac dysfunction (3%), and secondary malignancies (4%)
[13].
4. ABVD andNeutropenia
Neutropenia is a common complication of ABVD chemo-
therapy, but related complications including febrile neu-
tropenia (FN), neutropenic sepsis, and death are much less
frequent. The frequency of grade 3 or 4 neutropenia—
deﬁned by National Cancer Institute (NCI) common termi-
nology criteria for adverse events (CTCAE) as an absolute
neutrophil count (ANC) of <1.0–0.5 × 109/L and <0.5 ×
109/L, respectively—in randomized trials involving ABVD
chemotherapy ranges from 10 and 66% [13, 19, 20]. The
widerangeoftheoccurrenceofthisproblempossiblyreﬂects
the varied number of treatment cycles administered in these
trials. The incidence of febrile neutropenia or neutropenic
sepsis is not speciﬁed in these prospective studies. The
incidence of grade 3 infection (with or without neutropenia)
in a CALGB study was 2% [10]. A further study from
the Memorial Sloan Kettering Cancer Center reported an
8% rate of hospitalization due to neutropenia in patients
receiving ABVD chemotherapy [21].
The degree and duration of neutropenia is directly rela-
ted to the incidence and severity of febrile neutropenia and
infections [22]. Hence higher grades of neutropenia (grade
3 and 4) often lead to consideration of several strategies to
prevent associated complications and also to maintain high
dose intensity. There is a wide variability in the approach to
this problem, but the main strategies adopted to achieve this
goal include (1) dose delay/modiﬁcations (2) growth factor
(GF) support, (3) prophylactic antibacterial therapy.
4.1. Dose Modiﬁcations/Delays.Dose modiﬁcation was widely
adopted in the earlier studies comparing MOPP regimens
with ABVD [10, 23]. In the study reported by Canellos et
al., a 75% dose reduction of Dacarbazine and Vinblastine
is implemented for a leucocyte count of 2.5×109/L to
3.5×109/L at the time of the next dose. All chemotherapy
drugs were withheld if the WBC count is <2.5×109/L.
Despite a signiﬁcant number of patients in the MOPP
regimensrequiringdosealterationsordelays,morethan80%
of patients in the ABVD arm received >85% of the intended
dose of doxorubicin. Similarly, >80% compliance to theAdvances in Hematology 3
intendeddrugdeliveryisachievedwithABVDchemotherapy
in other clinical trials, suggesting that the treatment is
generally well tolerated.
Studies evaluating dose intensity in MOPP-based
chemotherapy for HL have shown that administering full
doses without treatment delays results in improved disease-
free and overall survival [24, 25]. However, the precise level
of dose intensity required to achieve these better outcomes
was not clearly deﬁned [26]. It was also shown in a cohort
of elderly patients, with a median age of 72yrs, receiving
ABVD-based chemotherapy, that those who received >65%
of the intended chemotherapy dose intensity had better
cause speciﬁc survival (CSS) and overall survival (OS) [27].
Some of the limitations of the above data are that these
studies are based on older chemotherapy regimens and the
exact dose intensity of ABVD chemotherapy required to
improve survival in HL is unknown. The Goldie-Coldman
hypothesis suggests that outcomes of cancer treatment are
improved with delivery of intended chemotherapy doses on
time [28] .As t r o n ga r g u m e n tc a nb em a d e ,t h a ti ti se v e n
more imperative to maintain a high dose intensity in this
chemosensitive malignancy [29]. The practice of routine
dose modiﬁcations/delays based on isolated neutropenia
abrogates the end point of delivering optimal doses on time.
However, this strategy is still an integral part of several
clinical trial designs in HL and we believe that this approach
needs reevaluation in the future.
4.2. ABVD and Growth Factor Support. While most ABVD-
based clinical trials initiated prior to the introduction of
GFs relied on dose alterations as the prime strategy to
counter neutropenia, subsequent studies relied on GFs as
the preferred way to maintain dose intensity and to prevent
neutropenia-related complications [14, 16, 20, 21]. Both
granulocyte colony stimulating factor (G-CSF) and granulo-
cyte macrophage colony stimulating factor (GM-CSF) have
been used to manage neutropenia in cancer chemotherapy,
but neither of them is found to be superior to the other
[30]. A Cochrane collaboration review evaluated the role of
colony stimulating factors (both G-CSF and GM-CSF) in
the treatment of malignant lymphomas [31]. A total of 2607
patients from 13 randomized control trials of patients with
bothHLandNon-Hodgkinlymphoma(NHL)wereincluded
in the review. The relative risk of severe neutropenia, febrile
neutropenia, and infections was lower, but freedom from
treatment failure (FFTF) and OS were not improved with
institution of GFs.
Several retrospective series suggest that growth factors
are not required to maintain high dose intensity in the
treatment of HL. A study from the University of Iowa
reported that FN developed only in 8 of 81 patients who
received a total of 894 treatments (half cycles) [32]. GF
support was used at the discretion of the clinician in 58
of 187 (37%) treatments associated with grade 3 or 4
neutropenia on the day of treatment, and dose modiﬁcations
were implemented in 29 (15.5%) of these treatments. Eight
of a total of 9 episodes of FN developed in patients with an
ANC of >1.0 × 109/L, none of whom received GFs. Of the
158 treatments administered without dose modiﬁcation, one
episode of FN occurred in the 58 treatments accompanied
by G-CSF and none in the 100 treatments given without G-
CSF support. This study concludes that neutropenic fever
is uncommon (1%) and unrelated to neutrophil count on
the day of ABVD treatment. In another study reported
from the Northwestern University, 61 out of 84 analyzed
patients proceeded with full dose ABVD therapy without
dose delay or G-CSF support, irrespective of the ANC on
the day of treatment [26]. Of note, monocytosis was used
as an indicator for imminent neutrophil recovery and was
found to be consistently elevated above the normal range,
across all treatment cycles. Febrile neutropenia was noted in
only 3 of 682 treatments (0.44%), despite a high number
of treatments (58%) delivered with an ANC of ≤1 × 109/L
on the day of ABVD treatment. Fifty-nine of these patients
reached 99% target dose intensity without GF support, and
the cycle duration and dose intensity in this group were
not statistically diﬀerent to a comparison group of twenty-
three patients who received routine empiric G-CSF. Of
note, nearly all patients received prophylactic trimethoprim-
sulfamethoxazole and ﬂuconazole which might have had a
protective eﬀect on systemic infections. Five-year event-free
and overall survival rates in the patients not receiving G-CSF
were 92.9% and 97.4%, respectively, and compared favorably
with those receiving G-CSF.
Two further retrospective studies from the UK also
concludethatapreponderantmajorityofpatientscompleted
their ABVD chemotherapy as planned, without GFs. In the
study by Boleti and Mead, 36 of 38 patients (95%) were able
tocompletetheirintendedABVDchemotherapywithoutany
increased risk of infective episodes [33]. About 79% of the
patients had one or more episodes of grade 3 or 4 neutrope-
nia, but the incidence of febrile neutropenia was only 0.57%
of all injection days (two injection days per cycle). Neither
GFs nor dose modiﬁcations were used to manage ABVD-
related neutropenia in this study. In the second study by
Nangalia et al., a total of 263 ABVD treatments (131.5 cycles)
were delivered to 24 patients [34]. None of these patients
received GFs and all patients received full dose of treatment
irrespective of their ANC, provided no other cytopenias or
toxicities were found on the day of treatment. Forty-seven
and eighteen percent of these patients had grade 3 and
grade 4 neutropenia, respectively, but the incidence of FN
was only 0.76%. Ninety-six percent of the patients received
the planned treatment without any dose reductions for
hematological toxicity, suggesting that it is possible to safely
and eﬀectively administer ABVD chemotherapy irrespective
of the neutrophil count on the day of treatment, and that
neutropenia is a poor surrogate for FN. The results of these
v a r i o u ss t u d i e sa r es u m m a r i z e di nTable 2.G r o w t hf a c t o r -
related side eﬀects, albeit minor, need to be seriously consid-
eredwhileinitiating therapywiththeseagents.Areportfrom
Martin et al. suggests an increased incidence of Bleomycin
pulmonary toxicity (BPT) in patients receiving G-CSF com-
pared to those without G-CSF (26% versus 9% P = .014)
[35]. Those patients with BPT have lower median 5-year
survival compared to unaﬀected patients (63% versus 90%).
Also, usage of GFs is associated with substantial costs, the
estimates of which vary widely. In the study by Evens et al.,4 Advances in Hematology
Table 2: Retrospective studies showing poor correlation between neutropenia and neutropenic complications.
Author Number of analyzed
patients without G-CSF
Grade 4 neutropenia (%)
patients/treatments1
%o ff e b r i l e
neutropenia2
%o fg r o w t hf a c t o r
supported treatments
DM3 due to grade 3 or 4
neutropenia
Chand et al. 81 43/7 1.0 6.5 15.5% of all treatments
Evens et al. 59 26/NA4 0.44 0 None
Boleti and Mead 28 37/NA 0.57 0 None
Nangalia et al. 24 NA/18 0.76 0 None
1. Treatments are half cycles, that is, two treatments per cycle.
2. Incidence of febrile neutropenia as percentage of overall treatments (half cycles).
3. DM: dose modiﬁcation.
4. NA: not available.
the net savings per patient on the pharmaceutical costs of G-
CSF use are estimated to be approximately $1800 [26].
The guidelines from the American Society of Clinical
Oncology (ASCO) and the European Organization for
Research and Treatment of Cancer (EORTC) recommend
the use of colony stimulating factors (CSF) as primary
prophylaxis in patients who have a >20% risk of developing
FN from chemotherapy [36, 37]. The ASCO guidelines
further recommend GFs for secondary prophylaxis in the
event of a prior neutropenic complication. These and other
datareferredabove,showthattheincidenceofFNinpatients
treated with ABVD is far less than 20%, suggesting that
primary prophylaxis with GFs is not indicated in these
patients. The added beneﬁts of cost savings and minimizing
toxicity make a strong argument for the omission of
colony stimulating factors as routine prophylaxis for isolated
neutropenia in the delivery of ABVD.
5. ABVD andProphylacticUse of Antibiotics
Another strategy to prevent FN and neutropenia-related
infectious complications, is the administration of prophylac-
ticantibacterialtherapy.Therearenorandomizedcontrolled
trials (RCTs) addressing the role of prophylactic antibiotics,
exclusively in patients receiving ABVD chemotherapy. How-
ever, several RCTs that include large numbers of HD patients
reported the beneﬁts of such a therapeutic intervention in
preventing neutropenic complications.
In the GEMIMA study, Bucaneve et al. analyzed 760
patients receiving chemotherapy for solid tumors, lym-
phomas, and acute leukemias, who were at increased risk
of developing prolonged neutropenia (more than 7 days)
[38]. These patients were stratiﬁed into two groups, those
with acute leukemia versus solid tumors or lymphoma,
and were randomized to receive either oral levoﬂoxacin or
placebo from the start of chemotherapy until the resolution
of neutropenia. A total of 212 patients with either Non
Hodgkin or Hodgkin lymphoma were recruited into this
study, but details of the exact number of patients with
HL and their chemotherapy regimens were not provided.
In both groups, levoﬂoxacin, compared to placebo, was
associatedwithasigniﬁcantlylowerrateofneutropenicfever,
microbiologically documented infections and bacteremias.
However, no survival beneﬁt was seen in patients receiving
antibiotic therapy.
IntheSIGNIFICANTstudybyCullenetal.,1565patients
with various solid tumors and lymphomas on chemotherapy
were randomized to receive levoﬂoxacin or placebo during
the anticipated neutropenic period [39]. A total of 59
patients (3.1%) had HL, and the majority of them received
ABVD chemotherapy. The primary end point was incidence
of fever, clinically documented as a temperature of >38◦C.
There was a signiﬁcantly lower incidence of febrile
episodes in those receiving levoﬂoxacin compared to placebo
(10.8% versus 15.2%; P = .01). A reduction of 38 days
of hospitalization was achieved for every 100 patients
treated with prophylactic levoﬂoxacin. Almost half of the
deaths reported in the study occurred in the ﬁrst month
of chemotherapy, and no survival beneﬁt was seen with
antibiotic usage. No data was presented regarding the
antibacterial resistance of the infecting organisms. Notably,
38% of the patients treated with levoﬂoxacin developed
fevers outside the expected time of neutropenia, raising
questionsofthepredictabilityofneutrophilnadircountsand
timing of antibiotic prophylaxis.
Gafter-Gvili et al. reported a metaanalysis of 95 clinical
trials between 1973 and 2004, in an attempt to address
the role of prophylactic antibiotic therapy in patients
receiving chemotherapy for various malignancies [40]. This
study suggested that there is a survival beneﬁt associated
with administration of antibiotics, particularly with ﬂuoro-
quinolones (relative risk, 0.52 (CI, 0.35 to 0.77)). A large
limitation of the study is that majority of the patients in
these clinical trials had hematological malignancies with
competing causes for an increased risk of infection, and data
on all cause mortality was missing in 10 out of 50 trials
comparing antibiotic prophylaxis with no intervention. The
RCTs by Bucaneve et al. and Cullen et al., which had a
large number of patients with HL, were not included in this
meta-analysis. In a subsequent smaller meta-analyses of four
trials comparing ﬂouroquinolones to placebo in patients
with solid tumors or lymphoma (including the GEMIMA
and SIGNIFICANT trials), the authors conclude that ﬂouro-
quinolones, when used as primary prophylaxis, at least for
the ﬁrst cycle of chemotherapy, confer a survival beneﬁt
[41].Advances in Hematology 5
The proportion of patients with HL in these studies
is small, and full details of the chemotherapy received by
them are not available. Retrospective data suggest that the
incidence of neutropenic complications in patients receiving
ABVD chemotherapy is low (<1%). Hence, we believe that
there is no role for routine administration of prophylactic
antibiotics for these patients.
6.ABVD-RelatedNeutropeniaandHIVPatients
Patients with human immunodeﬁciency virus (HIV) infec-
tion and acquired immune deﬁciency syndrome (AIDS) are
at an increased risk of developing HL. Though not an AIDS-
deﬁning illness, the incidence of HL is high in these patients
and even higher in the highly active antiretroviral therapy
(HAART) era [42]. “B” symptoms are more frequently
seen in patients with HIV-related HL, who often present
at advanced stages (stages III and IV) and carry a poorer
prognosis compared to HL patients without HIV infection
[43, 44]. Chemotherapy in this population has to be under-
taken with special care, in view of the immunocompromised
state of these patients.
No randomized data are available to conﬁrm the best
chemotherapy regimen in these patients. In a prospective
nonrandomized trial, 21 patients with HIV-related HL
received ABVD chemotherapy with primary G-CSF pro-
phylaxis, but no HAART therapy. Despite G-CSF prophy-
laxis, 52% of patients developed ≥ grade 3 toxicity. Six
patients (29%) developed opportunistic infections while
on chemotherapy, and 2 patients died from infectious
complications within 3 months of therapy. The median OS
was 18 months, far less than expected with ABVD therapy
for HL in the general population. Subsequent trials showed
that administering HAART along with chemotherapy is
associated with better outcomes [45]. In a retrospective mul-
ticenter study, 62 HIV-related HL patients were treated with
ABVD and HAART, and G-CSF was administered in 20% of
patients, at the discretion of the participating institutions.
Six patients (9.7%) died during the induction phase of
chemotherapy, largely from infectious complications. Five-
year EFS and OS were 71% and 76%, respectively, lower than
that expected in HL patients without HIV infection [46].
Clearly, the incorporation of HAART along with ABVD
chemotherapy improves survival and reduces the infection-
relatedcomplicationsinpatientswithHIV-relatedHL.There
arenodatatoprovetheroleofprimaryprophylaxiswithGFs
even in this population, but given their higher susceptibility
to infections, it would be reasonable to consider GF support
and or prophylactic antibiotics in this high-risk group.
7. Conclusions
Hodgkins lymphoma is exquisitely responsive to ABVD
chemotherapy, which results in a high cure rate. In order
to achieve maximum beneﬁt from this chemotherapy, it is
important to maintain optimal dose intensity. Severe neu-
tropenia is a well-recognized complication of this regimen,
which in theory could lead to an increased risk of morbidity
and mortality from infectious complications. There is a
wide variation in the several strategies adapted by physicians
to balance these conﬂicting priorities of maintaining dose
intensitywhilepreventingneutropeniaandrelatedcomplica-
tions. These strategies include dose modiﬁcations and/or GF
support and/or prophylactic antibiotics. Available evidence
suggests that although severe neutropenia is a common
occurrence with ABVD therapy, FN and other related
complications are rare in this setting. Patients can safely
proceed with ABVD chemotherapy in the presence of severe
neutropenia, without other therapeutic interventions. This
approach potentially avoids pulmonary toxicity and reduces
cost without loss of therapeutic eﬃcacy. Several ongoing
multicenter and international trials in Hodgkin lymphoma
currently utilize “full dose” ABVD without modiﬁcations
for neutropenia. These prospective trials should conﬁrm
or refute the safety ﬁndings of the retrospective analyses
described above. Special patient groups such as HIV patients
would need other concomitant measures such as HAART
therapy to reduce infectious complications. Though not
optimally studied, a strong case can be made to administer
GFs with or without prophylactic antibiotics in this special
population with a high rate of infectious complications.
References
[1] N. E. Caporaso, L. R. Goldin, W. F. Anderson, and O. Land-
gren, “Current insight on trends, causes, and mechanisms of
Hodgkin’s lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 117–
123, 2009.
[2] D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer
statistics, 2002,” Ca-A Cancer Journal for Clinicians, vol. 55,
no. 2, pp. 74–108, 2005.
[3] N. L. Harris, E. S. Jaﬀe, H. Stein et al., “A revised European-
American classiﬁcation of lymphoid neoplasms: a proposal
from the International Lymphoma Study Group,” Blood, vol.
84, no. 5, pp. 1361–1392, 1994.
[ 4 ]T .A .L i s t e r ,D .C r o w t h e r ,S .B .S u t c l i ﬀee ta l . ,“ R e p o r to fa
committee convened to discuss the evaluation and staging of
patients with Hodgkin’s disease: cotswolds meeting,” Journal
of Clinical Oncology, vol. 7, no. 11, pp. 1630–1636, 1989.
[5] C. Ferm´ e, H. Eghbali, J. H. Meerwaldt et al., “Chemotherapy
plus involved-ﬁeld radiation in early-stage Hodgkin’s disease,”
New England Journal of Medicine, vol. 357, no. 19, pp. 1916–
1927, 2007.
[6] C. Herbst, F. A. Rehan, C. Brillant et al., “Combined modality
treatment improves tumor control and overall survival in
patients with early stage Hodgkin’s lymphoma: a systematic
review,” Haematologica, vol. 95, no. 3, pp. 494–500, 2010.
[7] A. Engert, J. Franklin, H. T. Eich et al., “Two cycles of
doxorubicin, bleomycin, vinblastine, and dacarbazine plus
extended-ﬁeld radiotherapy is superior to radiotherapy alone
in early favorable Hodgkin’s lymphoma: ﬁnal results of the
GHSG HD7 trial,” Journal of Clinical Oncology, vol. 25, no. 23,
pp. 3495–3502, 2007.
[8] B. Klimm and A. Engert, “Combined modality treatment of
Hodgkin’s lymphoma,” Cancer Journal, vol. 15, no. 2, pp. 143–
149, 2009.
[9] J. Kuruvilla, “Standard therapy of advanced Hodgkin lym-
phoma,” Hematology, pp. 497–506, 2009.
[10] G.P.Canellos,J.R.Anderson,K.J.Propertetal.,“Chemother-
apy of advanced Hodgkin’s disease with MOPP, ABVD, or6 Advances in Hematology
MOPP alternating with ABVD,” New England Journal of
Medicine, vol. 327, no. 21, pp. 1478–1484, 1992.
[11] S.J.Horning,R.T.Hoppe,S.Breslin,N.L.Bartlett,B.William
Brown, and S. A. Rosenberg, “Stanford V and radiotherapy
for locally extensive and advanced Hodgkin’s disease: mature
results of a prospective clinical trial,” Journal of Clinical
Oncology, vol. 20, no. 3, pp. 630–637, 2002.
[12] V. Diehl, J. Franklin, M. Pfreundschuh et al., “Standard
and increased-dose BEACOPP chemotherapy compared with
COPP-ABVD for advanced Hodgkin’s disease,” New England
Journal of Medicine, vol. 348, no. 24, pp. 2386–2395, 2003.
[13] D. B. Duggan, G. R. Petroni, J. L. Johnson et al., “Randomized
comparison of ABVD and MOPP/ABV hybrid for the treat-
ment of advanced Hodgkin’s disease: report of an intergroup
trial,” Journal of Clinical Oncology, vol. 21, no. 4, pp. 607–614,
2003.
[14] P. G. Gobbi, A. Levis, T. Chisesi et al., “ABVD versus modiﬁed
Stanford V versus MOPPEBVCAD with optional and limited
radiotherapy in intermediate- and advanced-stage Hodgkin’s
lymphoma: ﬁnal results of a multicenter randomized trial
by the Intergruppo Italiano Linfomi,” Journal of Clinical
Oncology, vol. 23, no. 36, pp. 9198–9207, 2005.
[ 1 5 ]A .T h o m a s ,R .D .G i n g r i c h ,B .J .S m i t he ta l . ,“ 1 8 - ﬂ u o r o -
deoxyglucose positron emission tomography report inter-
pretation as predictor of outcome in diﬀuse large B-cell
lymphoma including analysis of ’indeterminate’ reports,”
Leukemia and Lymphoma, vol. 51, no. 3, pp. 439–446, 2010.
[ 1 6 ]P .W .M .J o h n s o n ,J .A .R a d f o r d ,M .H .C u l l e ne ta l . ,
“Comparison of ABVD and alternating or hybrid multidrug
regimensforthetreatmentofadvanced Hodgkin’slymphoma:
results of the United Kingdom Lymphoma Group LY09 Trial
(ISRCTN97144519),” Journal of Clinical Oncology, vol. 23, no.
36, pp. 9208–9218, 2005.
[17] M. Federico, S. Luminari, E. Iannitto et al., “ABVD compared
with BEACOPP compared with CEC for the initial treatment
of patients with advanced Hodgkin’s lymphoma: results from
the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial,”
Journal of Clinical Oncology, vol. 27, no. 5, pp. 805–811, 2009.
[ 1 8 ]P .W .M .J o h n s o n ,A .H o r w i c h ,A .J a c ke ta l . ,“ R a n d o m i s e d
Comparison of the Stanford V (SV) Regimen and ABVD
in the Treatment of Advanced Hodgkin Lymphoma (HL):
results from a UK NCRI Lymphoma Group Study, ISRCTN
64141244,” in Proceedings of the 50th ASH Annual Meeting
Abstracts, vol. 112, p. 370, 2008.
[19] A. Engert, P. Schiller, A. Josting et al., “Involved-ﬁeld radio-
therapy is equally eﬀective and less toxic compared with
extended-ﬁeld radiotherapy after four cycles of chemotherapy
inpatientswithearly-stageunfavorableHodgkin’slymphoma:
results of the HD8 trial of the German Hodgkin’s lymphoma
study group,” Journal of Clinical Oncology, vol. 21, no. 19, pp.
3601–3608, 2003.
[20] A. R. Dom´ ınguez, A. M´ arquez, J. Gum´ a et al., “Treatment of
stage I and II Hodgkin’s lymphoma with ABVD chemother-
apy: results after 7 years of a prospective study,” Annals of
Oncology, vol. 15, no. 12, pp. 1798–1804, 2004.
[21] D. J. Straus, C. S. Portlock, J. Qin et al., “Results of a prospec-
tive randomized clinical trial of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD) followed by radiation
therapy (RT) versus ABVD alone for stages I, II, and IIIA
nonbulky Hodgkin disease,” Blood, vol. 104, no. 12, pp. 3483–
3489, 2004.
[22] G. P. Bodey, M. Buckley, Y. S. Sathe, and E. J. Freireich,
“Quantitative relationships between circulating leukocytes
and infection in patients with acute leukemia,” Annals of
Internal Medicine, vol. 64, no. 2, pp. 328–340, 1966.
[23] A. Santoro, G. Bonadonna, P. Valagussa et al., “Long-term
results of combined chemotherapy-radiotherapy approach in
Hodgkin’s disease: superiority of ABVD plus radiotherapy
versus MOPP plus radiotherapy,” Journal of Clinical Oncology,
vol. 5, no. 1, pp. 27–37, 1987.
[24] P. Carde, F. R. MacKintosh, and S. A. Rosenberg, “A dose and
time response analysis of the treatment of Hodgkin’s disease
with MOPP chemotherapy,” Journal of Clinical Oncology, vol.
1, no. 2, pp. 146–153, 1983.
[25] R. E. N. van Rijswijk, C. Haanen, A. W. Dekker, A. J. de Meijer,
and J. Verbeek, “Dose intensity of MOPP chemotherapy and
survival in Hodgkin’s disease,” Journal of Clinical Oncology,
vol. 7, no. 12, pp. 1776–1782, 1989.
[26] A.M.Evens,J.Cilley, T.Ortizetal.,“G-CSFisnotnecessary to
maintainover99%dose-intensitywithABVDinthetreatment
of Hodgkin lymphoma: low toxicity and excellent outcomes
in a 10-year analysis,” British Journal of Haematology, vol. 137,
no. 6, pp. 545–552, 2007.
[27] O. Landgren, C. Algernon, U. Axdorph et al., “Hodgkin’s
lymphoma in the elderly with special reference to type
and intensity of chemotherapy in relation to prognosis,”
Haematologica, vol. 88, no. 4, pp. 438–444, 2003.
[28] J. H. Goldie and A. J. Coldman, “Quantitative model for
multiple levels of drug resistance in clinical tumors,” Cancer
Treatment Reports, vol. 67, no. 10, pp. 923–931, 1983.
[29] V. T. DeVita Jr., “The evolution of chemotherapy of lym-
phomas of adults,” Leukemia, vol. 1, no. 6, pp. 467–485, 1987.
[30] R. A. Beveridge, J. A. Miller, A. N. Kales et al., “A comparison
of eﬃcacy of sargramostim (yeast-derived RhuGM-CSF) and
ﬁlgrastim (bacteria-derived RhuG-CSF) in the therapeutic
setting of chemotherapy-induced myelosuppression,” Cancer
Investigation, vol. 16, no. 6, pp. 366–373, 1998.
[31] J. Bohlius, C. Herbst, M. Reiser, G. Schwarzer, and A. Engert,
“Granulopoiesis-stimulating factors to prevent adverse eﬀects
in the treatment of malignant lymphoma,” Cochrane Database
of Systematic Reviews, no. 4, Article ID CD003189, 2008.
[32] V. K. Chand, B. K. Link, J. M. Ritchie, M. Shannon, and J. E.
Wooldridge, “Neutropenia and febrile neutropenia in patients
with Hodgkin’s lymphoma treated with doxorubicin (Adri-
amycin), bleomycin, vinblastine and dacarbazine (ABVD)
chemotherapy,” Leukemia and Lymphoma, vol. 47, no. 4, pp.
657–663, 2006.
[33] E. Boleti and G. M. Mead, “ABVD for Hodgkin’s lymphoma:
full-dose chemotherapy without dose reductions or growth
factors,” Annals of Oncology, vol. 18, no. 2, pp. 376–380, 2007.
[34] J. Nangalia, H. Smith, and J. Z. Wimperis, “Isolated neutrope-
nia during ABVD chemotherapy for Hodgkin lymphoma does
not require growth factor support,” Leukemia and Lymphoma,
vol. 49, no. 8, pp. 1530–1536, 2008.
[35] W. G. Martin, K. M. Ristow, T. M. Habermann, J. P. Colgan, T.
E. Witzig, and S. M. Ansell, “Bleomycin pulmonary toxicity
has a negative impact on the outcome of patients with
Hodgkin’s lymphoma,” Journal of Clinical Oncology, vol. 23,
no. 30, pp. 7614–7620, 2005.
[36] T.J.Smith,J.Khatcheressian,G.H.Lymanetal.,“2006Update
of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline,” Journal
of Clinical Oncology, vol. 24, no. 19, pp. 3187–3205, 2006.
[37] M. S. Aapro, D. A. Cameron, R. Pettengell et al., “EORTC
guidelines fortheuseofgranulocyte-colony stimulatingfactor
to reduce the incidence of chemotherapy-induced febrile
neutropenia in adult patients with lymphomas and solidAdvances in Hematology 7
tumours,” E u r o p e a nJ o u r n a lo fC a n c e r , vol. 42, no. 15, pp.
2433–2453, 2006.
[38] G. Bucaneve, A. Micozzi, F. Menichetti et al., “Levoﬂoxacin
to prevent bacterial infection in patients with cancer and
neutropenia,” New England Journal of Medicine, vol. 353, no.
10, pp. 977–987, 2005.
[39] M. Cullen, N. Steven, L. Billingham et al., “Antibacterial
prophylaxis after chemotherapy for solid tumors and lym-
phomas,” New England Journal of Medicine, vol. 353, no. 10,
pp. 988–998, 2005.
[40] A. Gafter-Gvili, A. Fraser, M. Paul, and L. Leibovici, “Meta-
analysis: antibiotic prophylaxis reduces mortality in neu-
tropenic patients,” Annals of Internal Medicine, vol. 142, no.
12, part 1, pp. 979–995, 2005.
[41] A. Gafter-Gvili, M. Paul, A. Fraser, and L. Leibovici, “Antibi-
otic prophylaxis in neutropenic patients,” Israel Medical
Association Journal, vol. 9, no. 6, pp. 460–462, 2007.
[ 4 2 ] R .J .B i g g a r ,E .S .J a ﬀe, J. J. Goedert, A. Chaturvedi, R. Pfeiﬀer,
andE.A.Engels,“Hodgkinlymphomaandimmunodeﬁciency
in persons with HIV/AIDS,” Blood, vol. 108, no. 12, pp. 3786–
3791, 2006.
[43] R. Rubio, “Hodgkin’s disease associated with human immun-
odeﬁciency virus infection: a clinical study of 46 cases,”
Cancer, vol. 73, no. 9, pp. 2400–2407, 1994.
[44] U. Tirelli, D. Errante, R. Dolcetti et al., “Hodgkin’s disease and
human immunodeﬁciency virus infection: clinicopathologic
and virologic features of 114 patients from the Italian
Cooperative Group on AIDS and Tumors,” Journal of Clinical
Oncology, vol. 13, no. 7, pp. 1758–1767, 1995.
[45] J. Berenguer, P. Miralles, J. M. Ribera et al., “Characteristics
and outcome of AIDS-related hodgkin lymphoma before and
after the introduction of highly active antiretroviral therapy,”
Journal of Acquired Immune Deﬁciency Syndromes, vol. 47, no.
4, pp. 422–428, 2008.
[46] B. Xicoy, J. M. Ribera, P. Miralles et al., “Results of treat-
ment with doxorubicin, bleomycin, vinblastine and dacar-
bazine and highly active antiretroviral therapy in advanced
stage,humanimmunodeﬁciencyvirus-relatedHodgkin’s lym-
phoma,” Haematologica, vol. 92, no. 2, pp. 191–198, 2007.